ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

L-PAM Benefit To Post-Menopausal Patients Challenged

October 29, 1976

Advice Rolls In As Upton Proceeds With NCI Reorganization, Stands Firm On His Program

March 17, 1978

Letter To the Editor: Screening Revisited

May 20, 1994

PDX Shows 27% Response In T-Cell Lymphoma In Study

December 26, 2008

In Brief: NCI To Push “Cancer Prevention Awareness” This Month; Three RFPs Delayed For Changes

February 17, 1984

Klausner Unveils New NCI Structure, Aims To Change Institute’s “Ethos”

August 11, 1995